NEW YORK, March 29 – MiraiBio and BioSource International said Thursday they have agreed to jointly develop biological assays for use in drug discovery using Luminex’s LabMAP technology.
BioSource, based in Camarillo, Calif., will develop assay panels related to extracellular signaling, signal transduction, and cytokine research, while MiraiBio, formerly the Genetic Systems Division of Hitachi Software Engineering, will write software to accompany the assays.
The two companies will also combine their marketing, sales, and distribution efforts, and the first assays for cytokine research will become available in April.
"This partnership combines MiraiBio's expertise in laser-based systems and software integration with BioSource's expertise in kit development to provide our customers with the best possible solution," Leonard Klevan, MiraiBio’s president, said in a statement.Last December, MiraiBio, based in Alameda, Calif., signed a multi-year license for the LabMAP technology from Luminex. The technology uses microspheres, small lasers, digital processors, and software to perform up to 100 assays per drop of fluid.